Natraj Shanmugam, MD
Internal Medicine · College Station, TXNPI 1043449465
Payments from drug & device makers
Across 457 payments — averaging $27.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Novo Nordisk$3K
- AstraZeneca$977
- Dexcom, Inc.$754
- Lilly USA, LLC$484
- Bayer$418
- plus $2K from 21 others
What the payments were for
- Travel & lodging$2,26218%
- Food & beverage$9,92480%
- Education$1651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 107 | $4,392 |
| Novo Nordisk | 157 | $3,075 |
| AstraZeneca | 32 | $977 |
| Dexcom, Inc. | 25 | $754 |
| Lilly USA, LLC | 24 | $484 |
| Bayer | 10 | $418 |
| Amarin Pharma, Inc. | 14 | $365 |
| Zealand Pharma US, Inc. | 12 | $278 |
| Insulet Corporation | 14 | $218 |
| Cequr Corporation | 2 | $159 |
| Amgen | 4 | $142 |
| Boehringer Ingelheim | 5 | $133 |
| Valeritas, Inc. | 8 | $128 |
| AbbVie | 6 | $122 |
| Sanofi-aventis U.S. LLC | 7 | $112 |
| Abbott | 6 | $108 |
| IBSA Pharma Inc. | 7 | $107 |
| Johnson & Johnson | 3 | $91 |
| Mannkind Corporation | 4 | $76 |
| Optinose US, Inc. | 2 | $47 |
| Intuity Medical Inc | 2 | $37 |
| Sequel Med Tech, LLC | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| BETA Bionics, Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| NEW World Medical,inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$1,482
- Minimed 670G System$678
- Kerendia$247
- Ozempic$227
- RYBELSUS$125
- Vascepa$125
- FARXIGA$121
- Minimed 770G System$120
- CeQur Simplicity$118
- DEXCOM G6 TRANSMITTER$111
How this compares
$12,350 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 331 | $543,733 |
| JardianceEmpagliflozin | 138 | $163,250 |
| MounjaroTirzepatide | 79 | $107,492 |
| FarxigaDapagliflozin Propanediol | 62 | $61,726 |
| TrulicityDulaglutide | 29 | $53,140 |
| Tresiba Flextouch U-200Insulin Degludec | 58 | $49,339 |
| TradjentaLinagliptin | 59 | $46,683 |
| FiaspInsulin Aspart (Niacinamide) | 32 | $40,794 |
| V-Go 40Sub-Q Insulin Device, 40 Unit | 31 | $38,338 |
| JanuviaSitagliptin Phosphate | 28 | $32,679 |
| RybelsusSemaglutide | 30 | $31,990 |
| Budesonide ErBudesonide | 13 | $29,725 |
| Tresiba Flextouch U-100Insulin Degludec | 49 | $25,478 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $25,410 |
| VascepaIcosapent Ethyl | 26 | $25,325 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Rybelsus, Novolog | $3,075 | $638,738443 claims |
| Boehringer IngelheimJardiance, Tradjenta | $133 | $209,933197 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Lyumjev, Insulin Lispro | $484 | $196,685212 claims |
| AstraZenecaFarxiga | $977 | $61,72662 claims |
| AbbVieSynthroid | $122 | $14,365160 claims |
| BayerKerendia | $418 | $12,91518 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $19 | $1,459167 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in College Station
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.